NewBio Therapeutics, Inc. is an innovative bio-tech company located in the Zhangjiang Pharma Valley (Pudong, Shanghai).  The company was founded on Feb. 18, 2011, with registered capital of 20 million yuan.  Our R&D is focused on monoclonal antibody and antibody-drug conjugate (ADC) as anti-cancer therapeutics.  All pipeline drug candidates are proprietary.  Two programs are in phase I clinical trials, and five more programs are in either preclinical study or early discovery stages.  NewBio has collaborations with both domestic and international companies to develop novel targeted therapeutic drugs.

      The R&D and management team consists of senior scientists from the United States, with multiyear R&D and management experience in global biopharmaceutical companies. The company is a wholly foreign-owned enterprise.  The investors are experienced pharmaceutical veterans with rich biopharmaceutical investment experience.